Three miRNA Signatures in Glioma: From Molecular Mechanisms to Potential Clinical Application
ConditionGlioma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorRegina Elena Cancer Institute
About this trial
Individual overexpression of the three miRNAs negatively affects cell viability and proliferation mainly in grade III IDH-wild type cells, while in higher grade cells, the effect is more pronounced when the entire signature is overexpressed, individual and combined overexpression of the signature members is able to determine a significant reduction in both migration and invasion. Therefore, ectopic expression of the miRNAs identified by us has a negative impact on cell viability, proliferation and apoptosis, but above all on migration and invasion.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
histological diagnosis of glioma;
no concomitant primary tumor;
no metastatic disease;
availability of surgical material/tissue;
Disqualifiers
histological diagnosis of non-glial tumor;
patients with concomitant other solid tumors;
metastatic disease;
no surgical material/tissue available;
Trial population
Tissue samples from patients with glioma
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Dose-response curves
Cellular sensitivity to radiotherapy and temozolamide will be assessed by dose-response curves in both IDH-wild type and IDH-mutated patient-derived cell lines and primary cells.
Time frame
36 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Regina Elena Cancer Institute
Lead sponsor
University of Roma La Sapienza
Collaborator
San Camillo Hospital, Rome
Collaborator
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Collaborator
Neuromed IRCCS
Collaborator
Source ClinicalTrials.gov